By Daniella Parra Slate Medicines, a private biotech company developing new treatments for migraine and other headache disorders, has appointed Mark W. Hahn to its Board of Directors, they said. The company said Hahn brings more than 25 years of...

By Daniella Parra Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) said its Enhanced Brain Delivery (EBD) bispecific antibodies showed improved brain penetration in the treatment of Alzheimer’s disease. The company said it is collaborating with JCR Pharmaceuticals Co., Ltd. on EBD candidate development and studies through...

-HyProMag USA, a JV with CoTec Holdings Corp. (OTC: CTHCF), is building a U.S. rare-earth magnet supply chain through recycling instead of mining -Rare-earth magnets likely a scarce strategic asset in a market dominated by China -Real upside is creating...

Watch Video Highlights Below, or Click HERE:  Tech Edge hosted a fireside chat on at Pax8 Beyond 2026 in Salt Lake City with Oguo Atuanya, Corporate Vice President of Vendor Experience  at Pax8, and Daniel Danielli, Vice President of Global Scale Partnerships at...

By Exec Edge Editorial Staff AZA Law Firm opened its Dallas office at the Trammell Crow Center on January 1, 2026. The launch ended 32 years of Houston-only practice. Six months in, the office is tracking the public timeline managing...

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a...

By Karen Roman CareDx, Inc. (Nasdaq: CDNA) said it completed the acquisition of Naveris, which includes its leading product, NavDx, a blood-based test for viral-mediated cancer detection including human papillomavirus, and associated head and neck and anal cancers. NavDx is...

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to apply proprietary technology for stable clonal cell line generation. “Today’s news underscores our commitment to...

By Karen Roman SkylineDx said the FDA granted Breakthrough Device Designation to Merlin CP-GEP, the company’s gene expression profile test for risk assessment and clinical decision-making in patients with early-stage cutaneous melanoma. The Merlin CP-GEP is the first and only...